Candel Therapeutics, Inc. (CADL): R&D Expense
$30.50M
Year ended 2025-12-31
$49.13M
Trailing 12 months to 2026-06-30
+13.6%
3-year compound annual growth
+28.4%
5-year compound annual growth
| Period ended | R&D Expense | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $30.50M | +57.9% | 2026-03-12, From 2025-01-01 |
| 2024-12-31 | $19.31M | -21.2% | 2026-03-12, From 2024-01-01 |
| 2023-12-31 | $24.51M | +17.9% | 2025-03-13, From 2023-01-01 |
| 2022-12-31 | $20.79M | +37.0% | 2024-03-28, From 2022-01-01 |
| 2021-12-31 | $15.18M | +73.4% | 2023-03-30, From 2021-01-01 |
| 2020-12-31 | $8.75M | n/a | 2022-03-29, From 2020-01-01 |
R&D Expense at similar companies
| Company | Year ended | R&D Expense | Change YoY |
|---|---|---|---|
| Candel Therapeutics, Inc. (CADL) | 2025-12-31 | $30.50M | +57.9% |
| Acumen Pharmaceuticals, Inc. (ABOS) | 2025-12-31 | $104.89M | +11.8% |
| Kalaris Therapeutics, Inc. (KLRS) | 2025-12-31 | $30.75M | -31.7% |
| Pelthos Therapeutics Inc. (PTHS) | 2025-12-31 | $1.23M | +4.2% |
| Artiva Biotherapeutics, Inc. (ARTV) | 2025-12-31 | $69.54M | +38.2% |
| Palisade Bio, Inc. (PALI) | 2025-12-31 | $10.19M | +12.5% |
| Humacyte, Inc. (HUMA) | 2025-12-31 | $69.30M | -21.8% |
| Zura Bio Ltd (ZURA) | 2025-12-31 | $42.08M | +72.5% |
| Lineage Cell Therapeutics, Inc. (LCTX) | 2025-12-31 | $17.73M | +42.2% |
Compare CADL, ABOS, KLRS, PTHS side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗